Please login to the form below

Not currently logged in
Email:
Password:

Pfizer resurrects its OTC bid for Viagra in the UK

Confirms MHRA review of new pharmacist-supplied status has begun

Pfizer

Nearly nine years after its last attempt to make its blockbuster erectile dysfunction treatment available without a prescription, Pfizer is having another go.

UK regulator the MHRA has began reviewing an application to allow Viagra (sildenafil) to be made available without a prescription if supplied by a pharmacist - a move that would grant it ‘P’, though not OTC (over-the-counter), status.

If approved, Pfizer’s plans would see it continue to market the medicine as a prescription-only treatment under the Viagra brand and then it would provide pharmacists with training on dispensing sildenafil at a 50mg dose.

Pfizer’s UK medical director Dr Berkeley Phillips said: “The availability of pharmacist-supplied, non-prescription sildenafil could offer men a new and additional way to access a legitimate, long established, and well-studied treatment for erectile dysfunction.

“This could have further benefits as the condition may be an early warning sign of a more serious underlying condition, such as heart disease4, which may otherwise go undetected.”

Pfizer has previously tried for European approval to make Viagra available without a prescription, but those plans were scuppered in 2008 after regulatory advisors voiced concerns about misuse of the drug.

Article by
Dominic Tyer

28th March 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics